(Q38194944)

30 August 2017

1 reference

title

NKG2D signaling in cancer immunosurveillance (English)

1 reference

30 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615398%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Leticia Huergo-Zapico

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615398%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Andrea Acebes-Huerta

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615398%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Mónica Villa-Alvarez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615398%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Segundo Gonzalez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615398%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

English

0 references

publication date

3 March 2014

1 reference

International Journal of Cancer

30 August 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615398%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

136

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615398%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615398%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

1741-1750

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615398%20AND%20SRC:MED&resulttype=core&format=json

Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications.

9 June 2020

cites work

1 reference

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

Natural innate and adaptive immunity to cancer

21 January 2018

1 reference

21 January 2018

1 reference

NK cells and cancer immunosurveillance.

21 January 2018

1 reference

NKG2D function protects the host from tumor initiation

21 January 2018

1 reference

NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy

21 January 2018

1 reference

Roles of the NKG2D immunoreceptor and its ligands

21 January 2018

1 reference

DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells

21 January 2018

1 reference

A 2-Mb YAC contig and physical map of the natural killer gene complex on mouse chromosome 6.

21 January 2018

1 reference

Murine Nkg2d and Cd94 are clustered within the natural killer complex and are expressed independently in natural killer cells

21 January 2018

1 reference

Cloning of a mouse homolog of CD94 extends the family of C-type lectins on murine natural killer cells

21 January 2018

1 reference

The NKG2D receptor: sensing stressed cells

21 January 2018

1 reference

An activating immunoreceptor complex formed by NKG2D and DAP10

21 January 2018

1 reference

NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells

21 January 2018

1 reference

Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D

21 January 2018

1 reference

NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation

21 January 2018

1 reference

Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion

21 January 2018

1 reference

Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin

21 January 2018

1 reference

21 January 2018

The B7-CD28 superfamily

1 reference

Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells

21 January 2018

1 reference

The role of the NKG2D immunoreceptor in immune cell activation and natural killing

21 January 2018

1 reference

Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease.

21 January 2018

1 reference

Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells.

21 January 2018

1 reference

NKG2D induces Mcl-1 expression and mediates survival of CD8 memory T cell precursors via phosphatidylinositol 3-kinase

21 January 2018

1 reference

NKG2D signaling on CD8⁺ T cells represses T-bet and rescues CD4-unhelped CD8⁺ T cell memory recall but not effector responses

21 January 2018

1 reference

Bystander-activated memory CD8 T cells control early pathogen load in an innate-like, NKG2D-dependent manner

21 January 2018

1 reference

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

21 January 2018

1 reference

Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells

21 January 2018

1 reference

Human microRNA-1245 down-regulates the NKG2D receptor in natural killer cells and impairs NKG2D-mediated functions

21 January 2018

1 reference

Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1.

21 January 2018

1 reference

NKG2D is a costimulatory receptor for human naive CD8+ T cells.

21 January 2018

1 reference

NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment

21 January 2018

1 reference

Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation

21 January 2018

1 reference

A second lineage of mammalian major histocompatibility complex class I genes

21 January 2018

1 reference

ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor

21 January 2018

1 reference

Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D

21 January 2018

1 reference

Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D

21 January 2018

1 reference

Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice

21 January 2018

1 reference

Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.

21 January 2018

1 reference

Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D.

21 January 2018

1 reference

The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells.

21 January 2018

1 reference

Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D

21 January 2018

1 reference

Regulation of ligands for the NKG2D activating receptor

21 January 2018

1 reference

Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family

21 January 2018

1 reference

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

21 January 2018

1 reference

Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.

21 January 2018

1 reference

Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2.

21 January 2018

1 reference

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

21 January 2018

1 reference

DNA damage: a trigger of innate immunity but a requirement for adaptive immune homeostasis

21 January 2018

1 reference

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

21 January 2018

1 reference

Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D.

21 January 2018

1 reference

Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor

21 January 2018

1 reference

Mammalian SP/KLF transcription factors: bring in the family

21 January 2018

1 reference

Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T cells

21 January 2018

1 reference

HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.

21 January 2018

1 reference

Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor

21 January 2018

1 reference

Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium

21 January 2018

1 reference

Emerging roles for E2F: Beyond the G1/S transition and DNA replication

21 January 2018

1 reference

RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry

21 January 2018

1 reference

Cutting edge: the AP-1 subunit JunB determines NK cell-mediated target cell killing by regulation of the NKG2D-ligand RAE-1epsilon

21 January 2018

1 reference

Senescence of activated stellate cells limits liver fibrosis

21 January 2018

1 reference

p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells

21 January 2018

1 reference

Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells

21 January 2018

1 reference

Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance

21 January 2018

1 reference

Impairment of NK cell function by NKG2D modulation in NOD mice

21 January 2018

1 reference

Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells

21 January 2018

1 reference

Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways

21 January 2018

1 reference

Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction

21 January 2018

1 reference

Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function

21 January 2018

1 reference

The activating NKG2D ligand MHC class I-related chain A transfers from target cells to NK cells in a manner that allows functional consequences.

21 January 2018

1 reference

Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand

21 January 2018

1 reference

Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells

21 January 2018

1 reference

Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding

21 January 2018

1 reference

Proteolytic release of soluble UL16-binding protein 2 from tumor cells

21 January 2018

1 reference

TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells

21 January 2018

1 reference

Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression

21 January 2018

1 reference

Cellular expression, trafficking, and function of two isoforms of human ULBP5/RAET1G.

21 January 2018

1 reference

Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications

21 January 2018

1 reference

Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia

21 January 2018

1 reference

Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.

21 January 2018

1 reference

The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases

21 January 2018

1 reference

Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma

21 January 2018

1 reference

MMP9 mediates MICA shedding in human osteosarcomas

21 January 2018

1 reference

Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein

21 January 2018

1 reference

Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands.

21 January 2018

1 reference

In vivo selection for metastasis promoting genes in the mouse

21 January 2018

1 reference

High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas.

21 January 2018

1 reference

RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity

21 January 2018

1 reference

Exosome secretion: molecular mechanisms and roles in immune responses

21 January 2018

1 reference

Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands

21 January 2018

1 reference

Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells

21 January 2018

1 reference

Human tumor-derived exosomes down-modulate NKG2D expression.

21 January 2018

1 reference

Causes and consequences of microRNA dysregulation in cancer

21 January 2018

1 reference

Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D.

21 January 2018

1 reference

Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA

21 January 2018

1 reference

MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells

21 January 2018

1 reference

Decreased Dicer expression elicits DNA damage and up-regulation of MICA and MICB.

21 January 2018

1 reference

Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.

21 January 2018

1 reference

Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D.

21 January 2018

1 reference

Posttranslational regulation of the NKG2D ligand Mult1 in response to cell stress

21 January 2018

1 reference

Stress-regulated targeting of the NKG2D ligand Mult1 by a membrane-associated RING-CH family E3 ligase

21 January 2018

1 reference

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

21 January 2018

1 reference

Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells.

21 January 2018

1 reference

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

21 January 2018

1 reference

NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities

21 January 2018

1 reference

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

21 January 2018

1 reference

Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine

21 January 2018

1 reference

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy

21 January 2018

1 reference

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

21 January 2018

1 reference

CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer

21 January 2018

1 reference

IFN-dependent down-regulation of the NKG2D ligand H60 on tumors

21 January 2018

1 reference

Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells

21 January 2018

1 reference

Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors.

21 January 2018

1 reference

Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity

21 January 2018

1 reference

Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.

21 January 2018

1 reference

Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation

21 January 2018

1 reference

Raising the bar: the curative potential of human cancer immunotherapy.

21 January 2018

1 reference

Trial Watch: Adoptive cell transfer for anticancer immunotherapy

21 January 2018

1 reference

Targeting natural killer cells and natural killer T cells in cancer

21 January 2018

1 reference

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma

21 January 2018

1 reference

Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors

21 January 2018

1 reference

Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.

21 January 2018

1 reference

Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer

21 January 2018

1 reference

Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection

21 January 2018

1 reference

Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.

21 January 2018

1 reference

A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells

21 January 2018

1 reference

Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells

21 January 2018

1 reference

T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner

21 January 2018

1 reference

A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo

21 January 2018

1 reference

Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.

21 January 2018

1 reference

Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection

21 January 2018

1 reference

Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.

21 January 2018

1 reference

Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction

21 January 2018

1 reference

Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity

21 January 2018

1 reference

NKG2D ligands: key targets of the immune response.

21 January 2018

1 reference

Epigenetic therapy of cancer: past, present and future

21 January 2018

1 reference

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

21 January 2018

1 reference

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28775

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615398%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference